Nevertheless, the threshold of cGAS or STING activities must be maintained at normal levels to ensure effective anti-tumor responses and avoid facilitating the development of malignancy and side effects; therefore, developing STING agonists as adjuvants of cancer vaccines may be beneficial [199]. This evidence concerns the gene CGAS and cancer.